Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

NCT07303881 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT07303881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07303881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Lead sponsor
The First Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
December 31, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic disorder, irae, lung cancer (locally advanced or metastatic)